Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Massari

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Gut|May 2, 2020
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD studyCristina Bezzio, Simone Saibeni, Angela Variola, et al.
Inflammatory Bowel Diseases|January 17, 2017
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab BiosimilarGionata Fiorino, Natalia Manetti, Alessandro Armuzzi, et al.
Inflammatory Bowel Diseases|August 24, 2018
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across ItalyAlessandro Armuzzi, Gionata Fiorino, Angela Variola, et al.
European Journal of Gastroenterology & Hepatology|September 27, 2022
Continuous clinical remission with biologics in ulcerative colitis: the 'AURORA' comparison studyAndrea Cassinotti, Nicolò Mezzina, Annalisa De Silvestri, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 13, 2025
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE studyDaniela Pugliese, Giuseppe Privitera, Nicola Cersullo, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Gut|May 2, 2020
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD studyCristina Bezzio, Simone Saibeni, Angela Variola, et al.
Inflammatory Bowel Diseases|January 17, 2017
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab BiosimilarGionata Fiorino, Natalia Manetti, Alessandro Armuzzi, et al.
Inflammatory Bowel Diseases|August 24, 2018
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across ItalyAlessandro Armuzzi, Gionata Fiorino, Angela Variola, et al.
European Journal of Gastroenterology & Hepatology|September 27, 2022
Continuous clinical remission with biologics in ulcerative colitis: the 'AURORA' comparison studyAndrea Cassinotti, Nicolò Mezzina, Annalisa De Silvestri, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 13, 2025
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE studyDaniela Pugliese, Giuseppe Privitera, Nicola Cersullo, et al.
Pageof 3